Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | EEF2K | O00418 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8456337 | 0.71 | GSK3B (0.41) | SIRT2SIRT1SIRT3SIRT5ADORA2A | |
| SCHEMBL2446004 | 0.61 | GSK3B (0.48) | SIRT2SIRT1SIRT3SIRT5ADORA2A | |
| SCHEMBL5697079 | 0.58 | CA1 (0.31) | — | |
| SCHEMBL10329438 | 0.57 | APEX1 (0.59) | — | |
| Hydrochloric Acid SCHEMBL28143496 | 0.57 | ALDH1A1 (0.43) | SIRT2SIRT1SIRT3SIRT5EEF2K | |
| SCHEMBL3774169 | 0.57 | APEX1 (0.59) | — | |
| SCHEMBL14969113 | 0.56 | MAPK1 (0.40) | EEF2KADORA2AADORA2B | |
| SCHEMBL26452124 | 0.56 | GSK3B (0.39) | SIRT2SIRT1SIRT3SIRT5ADORA2A | |
| SCHEMBL5588716 | 0.55 | — | — | |
| SCHEMBL5588044 | 0.55 | HPGD (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4368705-A2 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | Cellectis (FR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240026376-A1 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | CELLECTIS (FR) | 2024-01-25 | — | — | US | disclosed |
| EP-3693384-B1 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | CELLECTIS (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-11820996-B2 | Method for generating T-cells compatible for allogenic transplantation | CELLECTIS (FR) | 2023-11-21 | — | — | US | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-06 | — | — | US | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11530272-B2 | Smart car devices, DE car polypeptides, side CARs and uses thereof | CHIMERA BIOENGINEERING, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-07 | — | — | US | disclosed |
| WO-2002029086-A2 | NUCLEIC ACID SEQUENCES DIFFERENTIALLY EXPRESSED IN CANCER TISSUE | BAYER CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
| US-20020034758-A1 | Oligonucleotide sequences for use in the diagnosis and treatment of colon cancer | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2002-03-21 | — | — | US | disclosed |
| US-6262333-B1 | USEFUL IN DETECTING COLON CANCER CELLS NON-INVASIVELY AT AN EARLY STAGE | BAYER CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6262334-B1 | USEFUL IN DETECTING COLON CANCER CELLS NON-INVASIVELY AT AN EARLY STAGE | BAYER CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1108021-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLORECTAL CANCER | Bayer Corporation (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-1086213-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLON CANCER | Bayer Corporation (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001011047-A2 | DNA SEQUENCES ISOLATED FROM HUMAN COLONIC EPITHELIAL CELLS | CA*TX, INC. (US) | 2001-02-15 | — | — | WO | disclosed |
| WO-2000047721-A2 | METHODS OF INDUCING INSULIN POSITIVE PROGENITOR CELLS | ONTOGENY, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000012702-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLORECTAL CANCER | BAYER CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999064576-A2 | HUMAN GENES DIFFERENTIALLY EXPRESSED IN COLON CANCER | BAYER CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109457-A1 | USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATION | CDK9, CDK19, CDKN1A | SIRT2 709/4885SIRT1 291/4885SIRT3 471/4885 |
| US-20020034758-A1 | Oligonucleotide sequences for use in the diagnosis and treatment of colon cancer | DCLRE1B, DNASE1L3, DDX21 | SIRT2 4681/4885SIRT1 4817/4885SIRT3 4679/4885 |
| US-11351161-B2 | Use of CDK9 inhibitors to reduce cartilage degradation | CDK9, CDK19, CDKN1A | SIRT2 709/4885SIRT1 291/4885SIRT3 471/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | SIRT2 1472/4885SIRT1 1626/4885SIRT3 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.